New Drug Decisions

Decisions on medicines are made by the Formulary Committee (FC) which is a subcommittee of the Area Drugs and Therapeutics Committee (ADTC).

The following webtables detail all decisions made on medicines since 2002. The content is broken down by therapeutic area, mirroring BNF chapters.

The SMC website should be accessed for full details of SMC decisions.

Gatro-intestinal System

Cardiovascular System

Respiratory System

Central Nervous System


Endocrine System

Obstetrics, Gynaecology and Urinary-tract Disorders

Malignant Disease and Immunosuppression

Nutrition and Blood

Musculoskeletal and Joint Diseases


Ear, Nose and Oropharynx



Recommendations on medical devices

Medicines are classified as:

Formulary Drugs

(a) Included in the Lothian Joint Formulary; first or second choice or in the prescribing notes

(b) Additional List: are approved for use in specialist units or when formulary drugs are ineffective, not tolerated or are contraindicated.

Non Formulary Drugs

(a) Not included: recommended by the SMC but not included in Lothian as suitable alternatives exist or an application has not been made to the Formulary Committee.  (Prescribing of these medicines can be approved through the non-approved medicines route.)

(b) Not recommended: not recommended by the SMC (as not cost effective), therefore, nor by the ADTC/Formulary Committee for use in Lothian.  (Prescribing of these medicines may be approved through the IPTR route, where appropriate.)

Unlicensed medicines are classified by a traffic light system as set out in the ADTC NHS Lothian 'Policy and procedures for the Use of unlicensed medicines' - see full document via this link.

RED: Specialist Use only

AMBER: General Use with restrictions

GREEN: Unrestricted General Use

BLACK: Not approved for use

As per SGHD/CMO(2012)1, Formulary Committee will classify medicines using the standard wording as below;

Included on the (LJF or Additional List or prescribing note) for the indication in question;

Included pending protocol;

Not Included on the Lothian Joint Formulary because the NHS Board decision is that the medicine does not represent sufficient added benefit to other comparator medicines to treat the condition in question;

Not Included on the Lothian Joint Formulary because clinicians do not support the formulary inclusion;

Not Included on the Lothian Joint Formulary because clinicians have not responded  to an invitation to apply for formulary inclusion for this medicine;

Not included pending protocol.